Chronische Störung aufgrund von übermäßigem Bakterienwachstum im Dünndarm (SIBO) - alternative Behandlungsmethoden und empfohlene Ernährung

The clinical presentations of small intestinal bacterial overgrowth (SIBO) frequently overlap with symptoms observed in a wide spectrum of other medical conditions, thereby complicating the establishment of a definitive diagnosis. A fundamental challenge lies in the absence of universally standardized, widely accepted criteria for identifying this microbial imbalance. Furthermore, SIBO may coexist with other chronic gastrointestinal disorders—such as Crohn’s disease—exacerbating symptoms characteristic of an acute inflammatory episode [3]. This comorbidity necessitates a thorough diagnostic evaluation alongside the implementation of a tailored therapeutic regimen that integrates selectively targeted antibiotics with precision probiotic supplementation. Notably, the clinical profile of SIBO is often misconstrued as irritable bowel syndrome (IBS), introducing additional complexities in both differential diagnosis and management, akin to the challenges encountered in Crohn’s disease [4]. A diagnosis of excessive bacterial proliferation is confirmed when the concentration of colony-forming units (CFU) in samples obtained from the proximal segments of the small intestine exceeds the threshold of 10⁵/ml. While the most reliable—though invasive—confirmatory method remains histopathological examination of jejunal biopsies, its technical demands and patient burden render it infrequently employed in routine clinical practice. Consequently, the diagnostic mainstay comprises noninvasive breath tests utilizing glucose solutions to measure hydrogen and methane levels in exhaled air. Despite the availability of multiple diagnostic modalities, each approach is encumbered by significant limitations, underscoring the urgent need for innovative, more accurate diagnostic solutions [5].

The management of **small intestinal bacterial overgrowth (SIBO)** is structured into three fundamental phases: **1. eradication of pathogenic microorganisms**, **2. induction of remission via broad-spectrum antibiotic therapy** (commonly rifaximin at 1000–1500 mg/day for 10–14 days, or alternatives such as amoxicillin or ciprofloxacin), and **3. sustained remission maintenance** through prokinetic agents that enhance intestinal motility, with potential antibiotic retreatment if symptoms recur. **Herbal and botanical interventions**, utilizing concentrated extracts and essential oils from plants like thyme, mugwort, lemon balm, barberry, ginger, and licorice, have demonstrated **near-equivalent efficacy** to conventional antibiotics in clinical settings [6]. While natural therapies may entail **higher financial costs** and **prolonged duration**, their **personalized application under medical supervision** offers a viable option for patients seeking non-pharmacological solutions. Dedicated SIBO supplements often feature **synergistic blends of phytotherapeutic compounds** (e.g., horsetail, pau d’arco, olive leaf, Chinese wormwood, or rhubarb root), whose **antimicrobial and anti-inflammatory properties** are substantiated by peer-reviewed research. Consultation with a healthcare provider is critical to tailor the approach to individual microbiological profiles and comorbidities.

Among the nutritional approaches that facilitate rapid remission and sustained management of small intestinal bacterial overgrowth (SIBO), the implementation of a specialized diet based on highly digestible and rapidly absorbed food substitutes stands out as particularly effective. These formulations typically comprise maltodextrin as the primary carbohydrate source, minimal quantities of high-quality plant-based oils, and a complement of free amino acids, vitamin-mineral complexes, and other bioactive compounds. While such a dietary regimen can significantly accelerate therapeutic outcomes by reducing bacterial load, its long-term adherence is complicated by low caloric density, limited palatability diversity, and potential micronutrient deficiencies. An alternative yet equally impactful strategy is the adoption of a low-FODMAP diet, which systematically excludes or restricts short-chain, poorly absorbed carbohydrates—including lactose, fructose, and fructans—thereby diminishing intestinal fermentation and promoting both qualitative and quantitative stabilization of the gut microbiota. Diagnosing SIBO presents clinical challenges due to its nonspecific symptomatology; however, multiple evidence-supported therapeutic avenues exist. Although antibiotic therapy remains the cornerstone of acute-phase treatment, natural interventions—such as targeted dietary modifications, probiotic supplementation, and lifestyle adjustments—play a critical role in long-term disease management. It is essential to emphasize that the dietary regimen of SIBO patients must be rigorously controlled and often subject to extensive restrictions, which, while potentially impacting quality of life, are indispensable for achieving durable clinical improvement.